Transdermal dopaminergic D 2 receptor agonist therapy in Parkinson's disease with N‐0923 TDS: A double‐blind, placebo‐controlled study

Author:

Hutton J. Thomas1,Metman Leo Verhagen2,Chase Thomas N.3,Juncos Jorge L.4,Koller William C.5,Pahwa Rajesh6,LeWitt Peter A.7,Samii Ali8,Tsui Joseph K.C.8,Calne Donald B.8,Waters Cheryl H.9,Calabrese Vincent P.10,Bennett James P.11,Barrett Richard12,Morris Jerry L.1

Affiliation:

1. Neurology Research & Education Center, Covenant Medical Center, Lubbock, Texas, USA

2. National Institutes of Health, NINDS, Bethesda, Maryland, USA, and Rush‐Presbyterian, St. Luke's Medical Center, Chicago, Ilinois, USA

3. National Institutes of Health, NINDS, Bethesda, Maryland, USA

4. Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA

5. Department of Neurology, University of Miami Medical Center, Miami, Florida, USA

6. Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA

7. Clinical Neuroscience Center, Southfield, Michigan, and Department of Neurology, Psychiatry, and Behavioral Neuroscience, Wayne State University School of Medicine, Detroit, Michigan, USA

8. Vancouver Hospital & Health Sciences Center, University of British Columbia, Vancouver, British Columbia, Canada

9. University of Southern California, Los Angeles, California, USA

10. Department of Neurology, McGuire VA Hospital, Richmond, Virginia, USA

11. Department of Neurology, University Of Virginia Medical Center, Charlottesville, Virginia, USA

12. Discovery Therapeutics, Inc., Richmond, Virginia, USA

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Reference27 articles.

1. SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE

2. The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson??s Disease

3. Levodopa therapy: Consequences of the nonphysiologic replacement of dopamine

4. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U‐91356A) in mptp‐exposed monkeys;Blanchet PJ;J Pharmacol Exp Ther,1995

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3